These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 7648647)
21. Development and characterization of nifedipine lipospheres. Vyas SP; Singh R; Dimitrijevic D Pharmazie; 1997 May; 52(5):403-4. PubMed ID: 9183794 [No Abstract] [Full Text] [Related]
22. Differences in bioavailability between 60 mg of nifedipine osmotic push-pull systems after fasted and fed administration. Anschütz M; Wonnemann M; Schug B; Toal C; Donath F; Pontius A; Pauli K; Brendel E; Blume H Int J Clin Pharmacol Ther; 2010 Feb; 48(2):158-70. PubMed ID: 20137768 [TBL] [Abstract][Full Text] [Related]
23. Benidipine hydrochloride--a new calcium-channel blocker of the dihydropyridine type. Pharmacokinetics, pharmacodynamics, tolerance and dose finding in mild to moderate hypertension. Maier-Lenz H; Rode H; Lenau H; Thieme G; Wölke E; Kobayashi H; Kobayashi S; Oka T Arzneimittelforschung; 1988 Nov; 38(11A):1757-63. PubMed ID: 3219156 [TBL] [Abstract][Full Text] [Related]
24. Reduced proteinuria after cessation of long-acting, osmotic release nifedipine GITS in diabetic nephropathy. Hess B Nephrol Dial Transplant; 1997 Aug; 12(8):1772-3. PubMed ID: 9269678 [No Abstract] [Full Text] [Related]
25. Clinical pharmacokinetics of nifedipine. Implications for the care of the elderly. Elliott HL; Meredith PA Drugs Aging; 1997 Dec; 11(6):470-9. PubMed ID: 9413704 [TBL] [Abstract][Full Text] [Related]
27. Effect of nifedipine on cerebral saturation parameters. Sal'nikov SN Bull Exp Biol Med; 2005 Oct; 140(4):423-4. PubMed ID: 16671571 [TBL] [Abstract][Full Text] [Related]
28. [Alterations in hepatitic metabolism induced by prolonged-action nifedipine in Mexican population]. Palma-Aguirre JA; Campos-Lara M; Chávez-Negrete A Gac Med Mex; 2002; 138(4):381-3. PubMed ID: 12200885 [No Abstract] [Full Text] [Related]
29. Therapeutically relevant blood pressure differences with two nifedipine (60 mg) osmotic delivery systems of differing design: three case reports. Pollak PT Int J Clin Pharmacol Ther; 2010 Jun; 48(6):400-4. PubMed ID: 20497748 [TBL] [Abstract][Full Text] [Related]
30. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? Grossman E; Messerli FH; Grodzicki T; Kowey P JAMA; 1996 Oct 23-30; 276(16):1328-31. PubMed ID: 8861992 [TBL] [Abstract][Full Text] [Related]
31. [Slow release nifedipine in treatment of hypertension. 24-hour effect on blood pressure and heart rate--treatment follow-up of 391 patients]. Bühler G; Wadepuhl M; Nandi K; Rosenthal J Fortschr Med; 1997 Aug; 115(24):37-8. PubMed ID: 9410819 [No Abstract] [Full Text] [Related]
32. Critical questions concerning the validity of the Bayer study report of "Differences in bioavailability between 60 mg of nifedipine osmotic push-pull systems after fasted and fed administration". Meyer MC Int J Clin Pharmacol Ther; 2010 Jun; 48(6):405-11; author reply 412-5, 416-8. PubMed ID: 20497749 [No Abstract] [Full Text] [Related]
33. Calcium antagonists: when the content does not justify the headline. Jackson G Br J Clin Pract; 1995; 49(6):283-4. PubMed ID: 8554947 [No Abstract] [Full Text] [Related]
34. Calcium channel blockers in systemic hypertension. Frishman WH; Charlap S; Michelson EL Am J Cardiol; 1986 Jul; 58(1):157-60. PubMed ID: 3524178 [No Abstract] [Full Text] [Related]
35. Case presentation. Initiation of gingival overgrowth by an increased daily dosage of nifedipine. Henderson JS; Guillot JL; Krolls SO; Parkel CO; Johnson RB Miss Dent Assoc J; 1994; 50(3):12-3. PubMed ID: 9569836 [No Abstract] [Full Text] [Related]
36. Development of nifedipine-loaded coated gelatin microcapsule as a long acting oral delivery. Li DX; Kim JO; Oh DH; Lee WS; Hong MJ; Kang JY; Choi JS; Woo JS; Yong CS; Choi HG Arch Pharm Res; 2009 Jan; 32(1):127-32. PubMed ID: 19183885 [TBL] [Abstract][Full Text] [Related]
37. [Hemodynamic and coronary changes induced by various slow-channel inhibitors in chronic coronary insufficiency: nifedipine, verapamil and bepridil]. Merillon JP; Duffloux MA; Eustigneff T; Pansard Y; Guiomard A; Zygelman M; Aumont MC; Gourgon R Therapie; 1981; 36(2):123-34. PubMed ID: 6270840 [No Abstract] [Full Text] [Related]
38. Assessment of bioavailability of experimental controlled release microcapsules of nifedipine. Mallick S; Gupta BK; Ghosal SK Acta Pol Pharm; 2000; 57(3):175-80. PubMed ID: 11143705 [TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of a novel nifedipine and pH-sensitive N-succinyl chitosan/alginate hydrogel bead in rabbits. Zhu XJ; Yuan W; Li P; Liu X; He JQ Drug Dev Ind Pharm; 2010 Dec; 36(12):1463-8. PubMed ID: 20704460 [TBL] [Abstract][Full Text] [Related]
40. Benefits and safety of long-acting calcium antagonists in coronary artery disease: the Action Trial. Fagard RH J Hypertens; 2005 Mar; 23(3):489-91. PubMed ID: 15716687 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]